Bertram Pitt
Cardiovascular Disease · Ann Arbor, MINPI 1316017742
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $201,057 of the $297,759 with a category attached, or 67.5%. 13 manufacturers reported payments, led by Vifor (international) Ltd. at 34.5% of the total. Reporting peaked in 2019 at $144,484 and has fallen 90.5% since, to $13,699 in 2025. Among cardiovascular disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 126 payments — averaging $2363.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor (international) Ltd.$103K
- Bayer$65K
- Sanofi US Services Inc.$48K
- Vifor Pharma, Inc.$36K
- Boehringer Ingelheim$14K
- Boehringer Ingelheim International GmbH$11K
- plus $22K from 7 others
Across 14 payments — averaging $476.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$4K
- Boehringer Ingelheim International GmbH$2K
What the payments were for
- Consulting fees$201,05768%
- Speaking & faculty fees$49,06516%
- Travel & lodging$45,63915%
- Food & beverage$1,9981%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor (international) Ltd. | 10 | $102,872 |
| Bayer | 43 | $64,566 |
| Sanofi US Services Inc. | 3 | $47,729 |
| Vifor Pharma, Inc. | 28 | $36,406 |
| Boehringer Ingelheim | 10 | $13,699 |
| Boehringer Ingelheim International GmbH | 3 | $10,500 |
| Astrazeneca UK Limited | 13 | $8,703 |
| Astrazeneca AB | 2 | $8,135 |
| Eli Lilly | 1 | $3,000 |
| Amgen | 10 | $1,540 |
| AstraZeneca | 1 | $523 |
| Lexicon Pharmaceuticals, Inc. | 1 | $64 |
| Merck | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veltassa$84,685
- Non-Covered$52,374
- SOTAGLIFLOZIN$47,673
- JARDIANCE$13,500
- Kerendia$8,265
- ONGLYZA$1,500
- LOKELMA$523
How this compares
$297,759 in reported general payments places this provider in the 95th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Ann Arbor
- Marschall RungeAnn Arbor$1.8M
- Vallerie McLaughlinAnn Arbor$947K
- Stanley ChetcutiAnn Arbor$573K
- David BachAnn Arbor$390K
- Victor MolesAnn Arbor$120K
- Salim HayekAnn Arbor$92K
- Ashwini KerkarAnn Arbor$84K
- Priya MehtaAnn Arbor$70K
- Raymond YeowAnn Arbor$61K
- Eric GoodAnn Arbor$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.